Black Diamond Therapeutics Inc (BDTX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize...

Form 8-K - Current report

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new...

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE...

Form 4 - Statement of changes in beneficial ownership of securities